Table of contents
- Trial overview
- Who is being studied
- Treatments and comparators
- What the trials measure
- Study design and phase
- What the results may mean
Trial overview
The available trial data show one authorised interventional study involving 13N-AMMONIA in people with refractory angina due to obstructive coronary artery disease.[1] The study is called the EXACT-2 Trial and is listed as Phase 2 with an enrollment of 109 participants.[1]
This trial is designed to evaluate the effects of XC001 in subjects with chronic angina caused by coronary artery disease, and 13N-AMMONIA is one of the listed study interventions.[1] The data do not describe 13N-AMMONIA as the main treatment being tested, but it is part of the study setup.[1]
Who is being studied
The target population is people with refractory angina due to obstructive coronary artery disease.[1] Refractory angina means chest pain that keeps happening even when standard treatment has not fully helped.[1]
The trial title also describes the population as subjects with chronic angina caused by coronary artery disease.[1] This means the study is focused on people with long-lasting chest pain related to poor blood flow in the heart arteries.[1]
Treatments and comparators
The intervention list includes Ammonia 13N given by intravenous administration, XC001 given by intracardiac use, and Flurpiridaz F 18 given by intravenous administration.[1] The brief summary says the trial evaluates the effect of XC001 after a one-time endocardial administration compared with a sham procedure group.[1]
A sham procedure is a comparison procedure that looks like treatment but does not include the active part being tested.[1] This helps researchers see whether the treatment really changes symptoms and test results.[1]
What the trials measure
The primary outcome is a composite endpoint based on the average of the proportions of subjects with a therapy response at Week 12 and Week 26 for XC001 compared with the sham procedure group.[1] A composite endpoint combines several important results into one main study measure.[1]
The brief summary says the study also looks at total exercise duration from a graded treadmill test, angina episodes recorded in a diary, and ischemic burden measured by PET stress imaging.[1] These measures help show whether people can exercise longer, have fewer chest pain episodes, and have less reduced blood flow in the heart.[1]
All treadmill and imaging results are assessed by blinded core labs.[1] Blinded review means the people checking the results do not know which group the participant was in, which helps reduce bias.[1]
Study design and phase
The study is listed as Phase 2 and interventional.[1] Phase 2 trials are usually used to learn more about how well a treatment works and to continue collecting response data in a defined patient group.[1]
The timing of the main response checks is at Week 12 and Week 26.[1] This means the study follows participants over several months to see how outcomes change after the procedure.[1]
What the results may mean
For patients, this trial is mainly about whether the study procedure can improve day-to-day symptoms and heart-related exercise limits in people with hard-to-treat angina.[1] The main focus is not just one test result, but a mix of symptom reports, exercise testing, and imaging findings.[1]
Because only one authorised trial is listed, the current evidence in the source data is limited to this Phase 2 study.[1] The trial is still important because it uses several outcome measures to understand both how patients feel and how the heart performs during stress.[1]
